Innoviva Price to Sales Ratio 2006-2020 | INVA

Historical PS ratio values for Innoviva (INVA) over the last 10 years. The current P/S ratio for Innoviva as of August 03, 2020 is .
Innoviva P/S Ratio Historical Data
Date Stock Price TTM Sales per Share Price to Sales Ratio
2020-08-03 13.81 5.23
2020-06-30 13.98 $2.64 5.30
2020-03-31 11.76 $2.51 4.69
2019-12-31 14.16 $2.30 6.15
2019-09-30 10.54 $2.34 4.51
2019-06-30 14.56 $2.30 6.33
2019-03-31 14.03 $2.33 6.03
2018-12-31 17.45 $2.30 7.58
2018-09-30 15.24 $2.18 7.00
2018-06-30 13.80 $2.04 6.77
2018-03-31 16.67 $1.93 8.62
2017-12-31 14.19 $1.81 7.85
2017-09-30 14.12 $1.58 8.92
2017-06-30 12.80 $1.45 8.83
2017-03-31 13.83 $1.22 11.29
2016-12-31 10.70 $1.10 9.71
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.372B $0.261B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $383.760B 18.29
Roche Holding AG (RHHBY) Switzerland $295.170B 0.00
Pfizer (PFE) United States $213.750B 13.36
Merck (MRK) United States $202.534B 14.48
Novartis AG (NVS) Switzerland $187.994B 14.62
Novo Nordisk (NVO) Denmark $153.839B 25.62
AstraZeneca (AZN) United Kingdom $146.388B 28.46
Eli Lilly (LLY) United States $143.745B 21.94
AbbVie (ABBV) United States $140.158B 10.20
Sanofi (SNY) $131.342B 15.61
GlaxoSmithKline (GSK) United Kingdom $101.144B 13.26
Bayer (BAYRY) Germany $61.459B 8.76
H Lundbeck (HLUYY) Denmark $7.199B 0.00